SCHEMBL1821690

SCHEMBL1821690

CONC(=O)C(C)(Oc1ccc(Oc2ccccc2)cc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.46
PPARA Q07869 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
MMP2 P08253 4/20 0.43
MMP13 P45452 4/20 0.43
MMP1 P03956 2/20 0.43
PARP10 Q53GL7 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LTA4H P09960 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818707 0.94 PPARA (0.47) PPARGPPARASMN1; SMN2NPC1RAB9A
SCHEMBL1820277 0.90 PPARG (0.47) PPARGPPARASMN1; SMN2MMP13MMP1
SCHEMBL1819286 0.89 PPARG (0.46) PPARGPPARASMN1; SMN2HPGDMEN1
SCHEMBL1819391 0.83 NPC1 (0.43) PPARGPPARASMN1; SMN2PDK1PDK2
SCHEMBL1821618 0.82 PPARA (0.44) PPARGPPARASMN1; SMN2PDK1PDK2
SCHEMBL1819151 0.81 CNR1 (0.41) PPARGPPARANPC1RAB9AMEN1
SCHEMBL1824421 0.79 BCHE (0.47) PPARGPPARARAB9AMEN1ALDH1A1
SCHEMBL1820711 0.79 MCL1 (0.43) PPARGPPARANPC1RAB9AMEN1
SCHEMBL1819039 0.79 PPARA (0.46) PPARGPPARASMN1; SMN2PDK1PDK2
SCHEMBL1818640 0.79 HDAC3 (0.58) PPARGPPARAMMP2MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 PPARG 1416/4885PPARA 2595/4885SMN1; SMN2 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.